Slide 1: 2025 Third quarter trading statement
2025 Third quarter trading statement October 2025
Slide 2: Disclaimer
Disclaimer This presentation contains certain statements that are, or may be These forward-looking statements and views may be based on a number deemed to be, “forward-looking statements” (including for purposes of of assumptions and, by their nature, involve known and unknown risks, the safe harbor
Slide 3: Dawn Allen, CFO: 2025 Third Quarter results
Dawn Allen CFO 2025 Third Quarter results
Slide 4: Third quarter 2025 revenue
Third quarter 2025 revenue £2.8bn 3.4% 1.8% /1.6% Q3 revenue Organic revenue growth1 Price / Volume Mix 9m results Continued progress driven by strong in-market 3.3% 2.2% /1.1% execution and innovation pipeline Organic revenue growth1 Price / Volume Mix Good growth in EMEA & LatAm and Asia-Pacific D
Slide 5: Q3 2025 organic revenue growth: +3.4%
Q3 2025 organic revenue growth : +3.4% 1 ORG1 +3.4% £m Organic revenue growth balanced between pricing and volume/mix 1.8% (2.3)% (0.4)% Net M&A dilution mainly divestment of 1.6% Price 2,799 Non-US Nicotine Replacement Therapy 2,780 Net M&A2 Translational business in 2025 Volume/Mix foreign exchang
Slide 6: Global portfolio delivering growth
Global portfolio delivering growth Organic Organic Q3 2025 revenue 9m 2025 revenue revenue growth1 revenue growth1 £m % £m % Oral Health 867 6.9% 2,595 7.4% VMS 422 4.9% 1,255 2.2% Pain Relief 647 3.7% 1,933 2.9% Respiratory Health 510 (1.8)% 1,403 (0.9)% Digestive Health 240 2.1% 731 0.5% Therapeut
Slide 7: North America
North America 35% • Q3 organic revenue growth1: 0.4% of Q3 2025 Revenue with +0.7% price and (0.3)% volume/mix • Q3 performance: £977m – Continued strength across Oral Health from innovation – Low-single digit growth in VMS Q3 2025 Revenue – Strong performance from Benefiber and Tums • 9m organic re
Slide 8: EMEA & LATAM
EMEA & LATAM 42% • Q3 organic revenue growth1: 5.3% of Q3 2025 Revenue with +3.5% price and +1.8% volume/mix • Q3 performance: £1,176m – Double digit growth in Sensodyne and Centrum – Broad based innovation-led growth across OTC from Q3 2025 Revenue Panadol, Voltaren and Otrivin – Decline in Therape
Slide 9: APAC
APAC 23% • Q3 organic revenue growth1: 5.1% of Q3 2025 Revenue with +0.7% price and +4.4% volume/mix • Q3 performance reflects: £646m – Continued strong performance in India and China – Mid-single digit growth in Oral Health and VMS Q3 2025 Revenue underpinned by innovation – Broad based growth acro
Slide 10: 2025 guidance
2025 guidance Around 3.5% organic revenue growth assuming a normal cold and flu season High-single digit organic operating profit growth Other modelling considerations Net Interest, Tax, and non- Net M&A and Translational controlling interest Foreign Exchange • Net interest cost expected to be • Net
Slide 11: Good Q3 performance and on track to deliver FY guidance
Good Q3 performance and on track to deliver FY guidance of around 3.5% organic revenue growth assuming a normal cold and flu season, and high-single digit organic operating profit growth Actions in the US set Haleon up for growth next year Building flexibility and agility in our P&L by unlocking pro
Slide 12: Appendix
Appendix
Slide 13: Glossary
Glossary Organic revenue growth and organic operating profit growth − Prior year and current year organic measures exclude revenue and operating profit attributable to MSAs relating to divestments and closure of production Our organic measures take our adjusted results and further exclude the impact
Slide 14: Historic quarterly growth across the categories
Historic quarterly growth across the categories Organic revenue growth1 2024 2025 Q1 Q2 Q3 Q4 FY Q1 Q2 HY Q3 Oral Health 10.6% 9.1% 8.2% 10.6% 9.6% 6.6% 8.7% 7.6% 6.9% VMS 9.9% 8.5% 3.7% 8.2% 7.6% 0.9% 0.9% 0.9% 4.9% Pain Relief (4.8)% (4.0)% 3.1% 7.4% 0.1% 2.6% 2.5% 2.5% 3.7% Respiratory Health (2.
Slide 15: Respiratory Health
Respiratory Health Weekly US market cold and flu (million units) C&F season 25 2022-23 2023-24 20 2024-25 15 2025-26 10 5 Winter season Off season Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Source: Circana MULOC+Ecom Cough Cold Flu Sinus is aggregate of Adult CCF, Kids CCF, Adult Sinus, and Kid
Slide 16: Reconciliation of organic growth
Reconciliation of organic growth Product categories Q3 2025 Digestive Therapeutic Oral Pain Respiratory Health and Skin Health 2025 vs 2024 (%) Health VMS Relief Health Other and Other Total Revenue growth 7.0 3.7 3.0 (12.2) 0.4 (1.7) 0.7 Organic adjustments - - - 10.2 - 2.3 2.3 Effect of exchange r
Slide 17: Reconciliation of quarterly organic growth
Reconciliation of quarterly organic growth North America EMEA & LatAm Q1 Q2 HY Q3 Q1 Q2 HY Q3 2025 vs 2024 (%) 2025 2025 2025 2025 2025 vs 2024 (%) 2025 2025 2025 2025 Revenue Growth (1.6) (9.3) (5.4) (2.0) Revenue Growth (4.3) (4.7) (4.5) 3.5 Organic Adjustments 2.3 1.8 2.0 0.4 Organic Adjustments
Slide 18: Q3 2025 results
Q3 2025 results Jo Russell Rakesh Patel Head of Investor Relations Director Joanne.c.Russell@Haleon.com Rakesh.x.Patel@Haleon.com +44 7787 392441 +44 7552 484646